Regional Burn Conferences Feature 12 RECELL® System Data Presentations by Prominent Burn Surgeons
October 28 2021 - 4:05PM
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative
medicine company that is developing and commercializing a
technology platform that enables point-of-care autologous skin
restoration for multiple unmet needs, announced today that 12
RECELL® System data presentations will be shared at the upcoming
Southern and Northeast Regional Burn Conferences. The presentations
will highlight a broad range of data including pediatric results,
cost-effectiveness and multiple case studies using the RECELL
System. The Southern Region Burn Conference will be held November
4-7 in New Orleans while the Northeast Region Burn Conference will
be held November 12-13 in Burlington, VT.
“The physician-initiated data being presented at these two
conferences underscores the depth and breadth of the RECELL
System’s utilization amongst burn surgeons across the U.S.,” said
Dr. Mike Perry, AVITA Medical’s Chief Executive Officer. “Patient
success stories that we hear on a regular basis from burn
specialists continue to fuel our teams’ enthusiasm and their
ongoing evaluation of the RECELL System platform for the
treatment of new indications, such as vitiligo and soft-tissue
injuries.”
RECELL System Presentations at Southern Region Burn
Conference
- Variations in Pediatric Length of
Stay: Evaluation of Cases and Real-world Data from Autologous Cell
Harvesting Device Use Comparted to Standard of Care in the
Treatment of Burns Requiring Inpatient Hospitalization. Author: N.
Kopari, Children’s Hospital, New Orleans
- Simplifying the Treatment Pathway
Algorithm and Number of Operations: Use of ASCS for Thermal Burn
Injuries. Author: W. Hickerson, Memphis, TN
- “Minimally Invasive” Skin Grafting
with Enzymatic Debridement and Autologous Skin Cell Spray. Authors:
G Gaweda, S Kahn, MUSC Department of Burn Surgery
- Histologic Changes of Skin
Biopsies After Autologous Skin Cell Suspension. Author: Laurent,
University Medical Center and LSU, New Orleans
- Outcomes for 43 Hand Burns Treated
with 2:1 Meshed & Epidermal Autografts when Donor Sites are
Abundant. Author: Yoo, University Medical Center and LSU, New
Orleans
- Early Post-Operative Mobilization
After Treatment of Burn Wounds with Autologous Skin Cell
Suspension. Authors: Kelly, S. Kahn, MUSC Department of Burn
Surgery
- The Use of Autologous Skin
Suspension in Thermal Injury to the Scalp: A Case Report. Authors:
Yoo, University Medical Center and LSU, New Orleans
- A Cost-Effectiveness Evaluation of
Real-World Data from Autologous Cell Harvesting Device Use
Comparted to Standard of Care in the Treatment of Burns Requiring
Inpatient Hospitalization. Author: Carson, Loyola Burn Center
Chicago
- Implementing Autologous Skin Cell
Suspension at an ABA Burn Center: A Comparison of Operative
Efficiency Using RECELL Versus Standard Split Thickness
Autografting. Author: D. Bell, University of Rochester Medical
Center
- Outcomes of Using Cultured
Epidermal Autograft (CEA) and Autologous Spray Cell Suspension
(ASCS) in Addition to Split. Authors: R. De Ayala, Grady
Hospital
RECELL System Presentations at Northeast Region Burn
Conference
- Optimal Donor Sites for Autologous Cell Suspension Device
(RECELL System) in Pediatric Burn Reconstruction. Author: B.
Temple, St. Christopher's Hospital for Children, Philadelphia,
PA
- A Cost-Effectiveness Evaluation of Autologous Cell Harvesting
Device Use Compared to Standard of Care in the Treatment of
Burns Requiring Inpatient Hospitalization: L. Rae, Temple Health
Burn Center, Philadelphia, PA
For more information about the RECELL System, please visit
www.RECELLSystem.com.
ABOUT AVITA MEDICAL, INC.AVITA Medical is a
regenerative medicine company with a technology platform positioned
to address unmet medical needs in burns, chronic wounds, and
aesthetics indications. AVITA Medical’s patented and proprietary
collection and application technology provides innovative treatment
solutions derived from the regenerative properties of a patient’s
own skin. The medical devices work by preparing a RES® REGENERATIVE
EPIDERMAL SUSPENSION, an autologous suspension comprised of the
patient’s skin cells necessary to regenerate natural healthy
epidermis. This autologous suspension is then sprayed onto the
areas of the patient requiring treatment.
AVITA Medical’s first U.S. product, the RECELL® System, was
approved by the U.S. Food and Drug Administration (FDA) in
September 2018. The RECELL System is indicated for use in the
treatment of acute thermal burns. The RECELL System is used to
prepare Spray-On Skin™ Cells using a small amount of a patient’s
own skin, providing a new way to treat severe burns, while
significantly reducing the amount of donor skin required. The
RECELL System is designed to be used at the point of care alone or
in combination with autografts depending on the depth of the burn
injury. Compelling data from randomized, controlled clinical trials
conducted at major U.S. burn centers and real-world use in more
than 10,000 patients globally reinforce that the RECELL System is a
significant advancement over the current standard of care for burn
patients and offers benefits in clinical outcomes and cost savings.
Healthcare professionals should read the INSTRUCTIONS FOR USE -
RECELL® Autologous Cell Harvesting Device
(https://recellsystem.com/) for a full description of indications
for use and important safety information including
contraindications, warnings, and precautions.
In international markets, our products are marketed under the
RECELL System brand to promote skin healing in a wide range of
applications including burns, chronic wounds, and aesthetics. The
RECELL System is TGA-registered in Australia and received CE-mark
approval in Europe. To learn more, visit www.avitamedical.com.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING
STATEMENTSThis press release includes forward-looking
statements. These forward-looking statements generally can be
identified by the use of words such as “anticipate,” “expect,”
“intend,” “could,” “may,” “will,” “believe,” “estimate,” “look
forward,” “forecast,” “goal,” “target,” “project,” “continue,”
“outlook,” “guidance,” “future,” other words of similar meaning and
the use of future dates. Forward-looking statements in this press
release include, but are not limited to, statements concerning,
among other things, our ongoing clinical trials and product
development activities, regulatory approval of our products, the
potential for future growth in our business, and our ability to
achieve our key strategic, operational and financial goal.
Forward-looking statements by their nature address matters that
are, to different degrees, uncertain. Each forward-looking
statement contained in this press release is subject to risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied by such statement. Applicable risks
and uncertainties include, among others, the timing of regulatory
approvals of our products; physician acceptance, endorsement, and
use of our products; failure to achieve the anticipated benefits
from approval of our products; the effect of regulatory actions;
product liability claims; risks associated with international
operations and expansion; and other business effects, including the
effects of industry, economic or political conditions outside of
the company’s control. Investors should not place considerable
reliance on the forward-looking statements contained in this press
release. Investors are encouraged to read our publicly available
filings for a discussion of these and other risks and
uncertainties. The forward-looking statements in this press release
speak only as of the date of this release, and we undertake no
obligation to update or revise any of these statements.
This press release was authorized by the review committee of
AVITA Medical, Inc.
FOR FURTHER INFORMATION:
U.S. MediaSam Brown, Inc.Christy CurranPhone
+1-615-414-8668christycurran@sambrown.com |
InvestorsWestwicke PartnersCaroline CornerPhone
+1-415-202-5678caroline.corner@westwicke.com |
|
|
O.U.S. MediaRudi MichelsonPhone +61 (0)3 9620
3333Mobile +61 (0)411 402 737rudim@monsoon.com.au |
|
Avita Medical (NASDAQ:RCEL)
Historical Stock Chart
From May 2024 to Jun 2024
Avita Medical (NASDAQ:RCEL)
Historical Stock Chart
From Jun 2023 to Jun 2024